Lymphocyte To High-Density Lipoprotein Ratio As A New Indicator Of Inflammation And Metabolic Syndrome

Haishan Chen*
Chongxiang Xiong
Xiaofei Shao*
Jing Ning
Peichun Gao
Hua Xiao
Yuning Chen
Ziliang Zou
Guobao Hong
Xiaolin Li
Mengjiao Shao
Jieli Sheng
Xingyan Yang
Xu You
Hequn Zou

Department of Nephrology, The Third Affiliated Hospital, Southern Medical University, Guangzhou 510630, People's Republic of China

*These authors contributed equally to this work

Purpose: Metabolic syndrome (MetS), which is a global public health problem, is a state of chronic low-grade inflammation. This study looked at the changes in hematological parameters and the predictive value of the lymphocyte to high-density lipoprotein cholesterol (HDL-C) ratio (LHR) as a new index in subjects with and without MetS in coastal cities in southern China.

Patients and methods: In this cross-sectional study, there were 852 participants (n = 598 with MetS and n = 254 without MetS). MetS was defined in accordance with the National Cholesterol Education Program, Adult Treatment Panel III (NCEP-ATP III) criteria.

Results: MetS was positively correlated with white blood cell count, total lymphocyte count, neutrophil count, red blood cell count, hematocrit, hemoglobin, and high-sensitivity C-reactive protein levels (p<0.05). In addition, there was a positive correlation between LHR and the number of metabolic risk factors for MetS. In a logistic regression analysis, LHR (odds ratio: 4.117; 95% CI: 2.766–6.309; p<0.001) was an independent predictor of MetS. When a receiver operating characteristic (ROC) curve analysis was used to assess the value of LHR for predicting MetS, the area under the curve yielded a cut-off value of 1.657, with a sensitivity of 65% and a specificity of 64% (p=0.0001).

Conclusion: In summary, MetS can involve changes in blood parameters, and LHR may be a useful marker of inflammation to assess the presence and severity of MetS.

Keywords: inflammation, marker, metabolic syndrome, lymphocyte to high-density lipoprotein cholesterol ratio

Introduction

MetS involves a complex group of metabolic disorders, including central obesity, systemic hypertension, insulin resistance, and atherogenic dyslipidemia (especially hypertriglyceridemia and decreased high-density lipoprotein cholesterol [HDL-C] levels), which increases the risk of cardiovascular and cerebrovascular diseases and diabetes.1,2

As the incidence and prevalence of MetS increase globally, this non-communicable disease has become a major health hazard worldwide.3 The underlying pathophysiology of MetS has several hypothetical mechanisms, the most widely accepted of which involves insulin resistance. Other potential mechanisms include low-grade chronic inflammation and oxidative stress, as MetS is a prothrombotic and proinflammatory state.4 A growing body of evidence suggests that changes in hematological parameters, including white blood cell (WBC), red blood cell (RBC),
and platelet counts, as markers of prothrombotic and proinflammatory states, may be associated with MetS. Reports on the changes in the number of lymphocytes in MetS patients are inconsistent. There have been reports of a decrease in the number of lymphocytes in MetS patients. However, some studies have found that lymphocytes proliferate and participate in the pathogenesis of patients.

Therefore, we suspected that the lymphocyte to HDL-C ratio (LHR) is a potential new inflammatory marker. We aimed to assess the associations of hematological parameters (including the new marker LHR) with the presence and severity of MetS.

**Methods**

**Study Population**

This cross-sectional survey was conducted from January to April 2018 in six communities in Wanzhai Town, Zhuhai City, on the southern coast of China. The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the Third Affiliated Hospital of Southern Medical University. All subjects signed a written informed consent form. A total of 852 (n = 254 with MetS and n = 598 without MetS) residents were enrolled in the survey.

MetS was diagnosed if at least three of the following five items of the National Cholesterol Education Program, Adult Treatment Panel III (NCEP ATP III) criteria were met:

1. Fasting triglyceride level ≥1.7 mmol/L or treated with drugs.
2. HDL-C levels <1.1 mmol/L for women and <0.9 mmol/L for men or treated with drugs.
3. Fasting blood glucose ≥5.6 mmol/L, treated with drugs, or previously diagnosed with type 2 diabetes mellitus.
4. Increased blood pressure: systolic blood pressure (SBP) ≥130 mmHg, diastolic blood pressure (DBP) ≥85 mmHg, treated with antihypertensive drugs, or previously diagnosed with hypertension.
5. Central obesity: waist circumference ≥90 cm for men and ≥80 cm for women.

Because the blood system is affected by many diseases, the following exclusion criteria were applied: use of antiplatelet drugs; abnormal liver function; abnormal renal function; heart disease; lung disease; gastrointestinal disease; autoimmune disease; malignant tumor; and acute or chronic infectious disease.

**Data Collection**

Questionnaires were used to collect data on age, gender, education, current smoking, current alcohol use, physical activity, and so on.

After resting for at least 5 mins, the blood pressure of each participant’s left arm was measured with a mercury sphygmomanometer three times, and the mean of the three readings was calculated. Waist circumference was measured at the midpoint between the lower rib edge at the midline and the top of the hip bone.

All blood samples were collected after at least 10 h of fasting overnight. Blood samples collected in ethylenediaminetetraacetic acid (EDTA) anticoagulation tubes were used to analyze blood routine parameters, and blood samples collected in tubes containing inert separation gels were used to analyze the blood biochemistry. All blood samples were transported to the central laboratory of the Third Affiliated Hospital of Southern Medical University within 3 h for analysis. Serum creatinine, fasting blood glucose, high-sensitivity C-reactive protein (hsCRP), serum total cholesterol, serum triglycerides, and serum HDL-C were measured by colorimetry. Whole blood cell counts were assessed using a Sysmex XN-1000 analyzer (Sysmex Corporation, Kobe, Japan). The lymphocyte to HDL-C ratio (LHR) was calculated manually.

**Statistical Analysis**

All data were analyzed using SPSS (version 20). Continuous variables are presented as mean ± standard deviation if they have a normal distribution, or as median and interquartile range if they do not. The categorical variables are expressed as frequencies and percentages.

The t-test was used to compare the differences in the means between the groups, while the Mann–Whitney U-test was used to compare the differences in the medians (These variables included Fasting plasma glucose, Serum triglycerides, Eosinophilic count, Basophilic count and hsCRP). The chi-square (χ²) test was used for comparison of categorical variables. Correlation analysis was used to determine the association between MetS and variables (especially the hematological indicators). Binomial logistic regression analysis was used to identify the independent predictors of MetS, controlling for confounders. A receiver operating characteristic (ROC) curve analysis was
used to assess the value of the novel indicator LHR for predicting MetS and to obtain the best cutoff value. Two-tailed \( p \) values <0.05 were considered significant.

**Results**

As can be seen from Table 1, compared with the MetS(-) group, the MetS(+) group was significantly older, had significantly higher proportions of men and smokers, and had significantly higher waist circumference, blood pressure, fasting plasma glucose, and triglyceride levels, while the proportion of individuals with an educational level of high school or above and HDL-C levels were significantly reduced \( (p<0.01). \) In addition, in the MetS(+) group, the WBC count (and the counts of the WBC subcomponents), RBC count, hemoglobin, hematocrit, and hsCRP were also significantly increased. However, there were no significant differences in platelet count, platelet distribution width, or mean platelet volume \( (p>0.05). \)

As shown in Table 2, in the correlation analysis, the severity of MetS was significantly positively correlated with WBC count, neutrophil count, total lymphocyte count, RBC count, hemoglobin, hematocrit, hsCRP, age, and education. Additionally, the correlation coefficient for LHR and MetS was 0.251 \( (p<0.001). \)

To determine the independent predictors of the presence of MetS, the abovementioned continuous variables were subjected to binomial logistic regression analysis. The results showed that LHR, hemoglobin, and hsCRP were independent predictors of MetS (Table 3). As the outcome variable may be affected by many confounding factors, age, male gender, current smoking, current alcohol use, physical activity, and education level were adjusted for in Model 2, and Model 3 also adjusted for fasting blood glucose and waist circumference.

**Figure 1** shows that the severity of MetS was proportional to lymphocyte to high-density lipoprotein ratio (LHR).

As shown in **Figure 2**, a ROC curve analysis was used to assess the value of three inflammatory markers (LHR, total lymphocyte count, and hsCRP) for predicting MetS in the study population.

The analysis showed that the cutoff value of LHR was 1.657, the sensitivity was 65%, the specificity was 64%,

---

**Table 1** Sociodemographic And Clinical Characteristics Of The Study Population (Frequency And Percentage/Mean ± Standard Deviation)

<table>
<thead>
<tr>
<th>Variable</th>
<th>MetS(-) (n = 598)</th>
<th>MetS(+) (n = 254)</th>
<th>( p )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>47.67±0.45</td>
<td>56.48±0.53</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>205(34.28)</td>
<td>108(42.52)</td>
<td>0.022</td>
</tr>
<tr>
<td>Current smoking, n (%)</td>
<td>61(10.20)</td>
<td>38(14.96)</td>
<td>0.047</td>
</tr>
<tr>
<td>Current alcohol use, n (%)</td>
<td>22(3.68)</td>
<td>10(3.94)</td>
<td>0.856</td>
</tr>
<tr>
<td>Educational attainment – high school or above, n (%)</td>
<td>293(49.00)</td>
<td>88(34.64)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Physical activity, n (%)</td>
<td>338(56.52)</td>
<td>158(62.20)</td>
<td>0.124</td>
</tr>
<tr>
<td>Waist circumference, cm</td>
<td>83.44±0.38</td>
<td>93.72±0.52</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Systolic blood pressure (SBP), mmHg</td>
<td>126.15±0.72</td>
<td>144.15±1.03</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Diastolic blood pressure (DBP), mmHg</td>
<td>80.46±0.43</td>
<td>89.69±0.56</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Fasting plasma glucose, mmol/L</td>
<td>4.85(4.56–5.14)</td>
<td>5.70(4.99–6.59)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Serum triglycerides, mmol/L</td>
<td>1.185(0.89–1.53)</td>
<td>2.09(1.62–2.27)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>High-density lipoprotein cholesterol (HDL-C), mmol/L</td>
<td>1.53±0.01</td>
<td>1.32±0.02</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>White blood cell count, 10(^9)/L</td>
<td>6.41±0.06</td>
<td>7.03±0.11</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Neutrophil count, 10(^9)/L</td>
<td>3.44±0.05</td>
<td>3.77±0.08</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Lymphocyte count, 10(^9)/L</td>
<td>2.28±0.03</td>
<td>2.52±0.04</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Eosinophilic count, 10(^9)/L</td>
<td>0.13(0.08–0.20)</td>
<td>0.15(0.09–0.24)</td>
<td>0.003</td>
</tr>
<tr>
<td>Basophilic count, 10(^9)/L</td>
<td>0.02(0.02–0.03)</td>
<td>0.03(0.02–0.04)</td>
<td>0.003</td>
</tr>
<tr>
<td>Mononuclear count, 10(^9)/L</td>
<td>0.50±0.01</td>
<td>0.52±0.01</td>
<td>0.04</td>
</tr>
<tr>
<td>Red blood cell count, 10(^12)/L</td>
<td>4.85±0.02</td>
<td>4.96±0.03</td>
<td>0.006</td>
</tr>
<tr>
<td>Hemoglobin, g/L</td>
<td>139.5±0.55</td>
<td>145.9±0.82</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Hematocrit</td>
<td>0.43±0.001</td>
<td>0.45±0.002</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Platelet count, 10(^9)/L</td>
<td>265.55±2.45</td>
<td>267.1±3.63</td>
<td>0.723</td>
</tr>
<tr>
<td>Mean platelet volume, fl</td>
<td>10.34±0.04</td>
<td>10.32±0.05</td>
<td>0.820</td>
</tr>
<tr>
<td>Platelet distribution width, fl</td>
<td>11.92±0.08</td>
<td>12.07±0.13</td>
<td>0.303</td>
</tr>
<tr>
<td>hypersensitive C-reactive protein (hsCRP), mg/L</td>
<td>1.09(0.001–1.98)</td>
<td>1.93(1.19–2.93)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>
Hemoglobin can cause leukocytosis. Which are released by perivascular white adipose tissue, inflammatory factors, leukocyte properties are altered, with an increase in the tendency to adhere to the vascular endothelium, which may result in increased capillary leukocytosis and a subsequent increase in vascular resistance. Adiponectin inhibits the production of macrophage chemokine ligands and reduces the recruitment of T-lymphocytes in atherosclerosis. Low plasma adiponectin levels in obese individuals often lead to chronic inflammation, resulting in metabolic disorders. In addition, mature curve analysis showed that LHR had a higher predictive value for MetS than total lymphocyte count and hsCRP. To the best of our knowledge, this study is the first clinical study to focus on the relationship between LHR as a novel and indirect inflammatory marker and the presence and severity of MetS.

Our data were consistent with some of the previous reports of changes in blood parameters in patients with MetS. These associations between blood parameters and MetS can be explained by the contribution of insulin resistance to the development of MetS. Insulin influences metabolism and proliferation. Insulin and insulin growth factors, I and II can promote the proliferation of RBC and WBC.

Elevated WBC counts may result in low levels of chronic inflammation that impair endothelial function and thereby affect the production of nitric oxide and prostacyclin, ultimately leading to vasoconstriction and hypertension. Under stimulation by inflammatory factors, leukocyte properties are altered, with an increase in the tendency to adhere to the vascular endothelium, which may result in increased capillary leukocytosis and a subsequent increase in vascular resistance. Adiponectin inhibits the production of macrophage chemokine ligands and reduces the recruitment of T-lymphocytes in atherosclerosis. Low plasma adiponectin levels in obese individuals often lead to chronic inflammation, resulting in metabolic disorders. In addition, mature

### Table 2 Correlation Analysis Between MetS Severity and Hematological Indicators

<table>
<thead>
<tr>
<th>Variable</th>
<th>R</th>
<th>p</th>
<th>Grading Of The Correlation Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>White blood cell count</td>
<td>0.143</td>
<td>&lt;0.001</td>
<td>Small</td>
</tr>
<tr>
<td>Neutrophil count</td>
<td>0.101</td>
<td>&lt;0.001</td>
<td>Small</td>
</tr>
<tr>
<td>Lymphocyte count</td>
<td>0.142</td>
<td>&lt;0.001</td>
<td>Small</td>
</tr>
<tr>
<td>Eosinophilic count</td>
<td>0.084</td>
<td>&lt;0.001</td>
<td>Small</td>
</tr>
<tr>
<td>Basophilic count</td>
<td>0.093</td>
<td>&lt;0.001</td>
<td>Small</td>
</tr>
<tr>
<td>Mononuclear count</td>
<td>0.057</td>
<td>&lt;0.05</td>
<td>Small</td>
</tr>
<tr>
<td>Red blood cell count</td>
<td>0.123</td>
<td>&lt;0.001</td>
<td>Small</td>
</tr>
<tr>
<td>Hemoglobin</td>
<td>0.172</td>
<td>&lt;0.001</td>
<td>Small</td>
</tr>
<tr>
<td>Hematocrit</td>
<td>0.171</td>
<td>&lt;0.001</td>
<td>Small</td>
</tr>
<tr>
<td>Lymphocyte to HDL-C ratio</td>
<td>0.251</td>
<td>&lt;0.001</td>
<td>Small</td>
</tr>
<tr>
<td>hsCRP</td>
<td>0.279</td>
<td>&lt;0.001</td>
<td>Small</td>
</tr>
<tr>
<td>Smoking</td>
<td>0.077</td>
<td>&lt;0.05</td>
<td>Small</td>
</tr>
<tr>
<td>Education attainment – high school or above</td>
<td>−0.132</td>
<td>&lt;0.001</td>
<td>Small</td>
</tr>
<tr>
<td>Age</td>
<td>0.314</td>
<td>&lt;0.001</td>
<td>Medium</td>
</tr>
<tr>
<td>Male</td>
<td>−0.078</td>
<td>&lt;0.05</td>
<td>Small</td>
</tr>
</tbody>
</table>

Abbreviation: hsCRP, hypersensitive C-reactive protein.

and the area under the curve was 0.694 (p<0.001; 95% confidence interval [CI]: 0.655–0.732). The area under the curve values for total lymphocyte count and hsCRP were 0.609 (p<0.001; 95% CI: 0.568–0.650) and 0.675 (p<0.001, 95% CI: 0.638–0.713), respectively.

### Discussion

The main findings of this study were as follows: (i) The hematological parameters of patients with MetS were partially altered compared with those of patients without MetS. These changes mainly involved the parameters related to WBC and RBC counts and the counts of their subcomponent cells, while the platelet-related parameters were unchanged. (ii) LHR increased as the number of MetS risk factors increased, showing a positive correlation. (iii) ROC curve analysis showed that LHR had a higher predictive value for MetS than total lymphocyte count and hsCRP. To the best of our knowledge, this study is the first clinical study to focus on the relationship between LHR as a novel and indirect inflammatory marker and the presence and severity of MetS.

Our data were consistent with some of the previous reports of changes in blood parameters in patients with MetS. These associations between blood parameters and MetS can be explained by the contribution of insulin resistance to the development of MetS. Insulin influences metabolism and proliferation. Insulin and insulin growth factors, I and II can promote the proliferation of RBC and WBC.

Elevated hematocrit increases blood viscosity and peripheral blood flow resistance, further limiting glucose, insulin, and oxygen transport to metabolically active tissues and increasing the risk of insulin resistance. Hemoglobin can induce vasoconstriction by limiting nitric oxide in vascular smooth muscle cells, which explains the positive correlation between hemoglobin levels and hypertension.

Elevated WBC counts may result in low levels of chronic inflammation that impair endothelial function and thereby affect the production of nitric oxide and prostacyclin, ultimately leading to vasoconstriction and hypertension. Under stimulation by inflammatory factors, leukocyte properties are altered, with an increase in the tendency to adhere to the vascular endothelium, which may result in increased capillary leukocytosis and a subsequent increase in vascular resistance. Adiponectin inhibits the production of macrophage chemokine ligands and reduces the recruitment of T-lymphocytes in atherosclerosis. Low plasma adiponectin levels in obese individuals often lead to chronic inflammation, resulting in metabolic disorders. In addition, mature

### Table 3 Binomial Logistic Regression Analysis Showing Independent Predictors Of MetS

<table>
<thead>
<tr>
<th>Variable</th>
<th>Model 1</th>
<th></th>
<th>Model 2</th>
<th></th>
<th>Model 3</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR (95% CI)</td>
<td>p</td>
<td>OR (95% CI)</td>
<td>p</td>
<td>OR (95% CI)</td>
<td>p</td>
</tr>
<tr>
<td>Hemoglobin</td>
<td>1.022 (1.010–1.035)</td>
<td>&lt;0.001</td>
<td>1.041 (1.023–1.059)</td>
<td>&lt;0.001</td>
<td>1.032 (1.012–1.053)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>LHR</td>
<td>2.461 (1.914–3.164)</td>
<td>&lt;0.001</td>
<td>3.140 (2.360–4.177)</td>
<td>&lt;0.001</td>
<td>2.917 (2.110–4.033)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>hsCRP</td>
<td>1.068 (1.030–1.107)</td>
<td>&lt;0.001</td>
<td>1.056 (1.019–1.094)</td>
<td>&lt;0.05</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Notes: Model 1: Not adjusted. Model 2: Adjusted for age, male gender, current smoking, current alcohol use, physical activity, and education attainment. Model 3: Adjusted for age, male gender, current smoking, current alcohol use, physical activity, education attainment, fasting blood glucose, and waist circumference.

Abbreviations: LHR, lymphocyte to high-density lipoprotein cholesterol ratio; hsCRP, hypersensitive C-reactive protein.
adipocytes stimulate the migration of adipose tissue lymphocytes, and these lymphocytes can potentiate insulin-mediated lipogenesis by local paracrine signaling.\(^{37}\)

HDL-C can prevent the migration of macrophages in atherosclerosis and promote the export of oxidized-LDL-C from these cells, so it has anti-inflammatory and anti-lipid properties.\(^{13}\) Therefore, LHR may be a novel marker of inflammation that can predict the occurrence and severity of MetS. LHR is an easily accessible marker that is less expensive than other inflammation markers such as cytokines (e.g., monocyte chemoattractant protein [MCP]-1). However, LHR has limitations, as it may be affected by many systemic inflammatory or infectious diseases as well as anti-inflammatory and anti-lipid treatments.

Our research has several limitations. First, this study is a single-center cross-sectional epidemiological survey that lacks an analysis of the causal relationship between LHS and MetS. A prospective cohort study is needed to clarify this issue. The absence of simultaneous assessment of cytokines, adipokines, CRP, and other inflammatory markers is another limitation of this study. Additionally, because we only studied residents who were willing to participate, the residents with more comorbidities and those who were not employed may have participated at a higher rate, which may have led to selection bias. In addition, we only screened the study population based on the study examination and their medical history, which may have affected the accuracy of the results (cardiac ultrasound, chest radiographs, tumor markers, etc. need to be added to exclude specific diseases).

**Funding**

This study was supported by Risk factors and prediction model of chronic kidney disease caused by metabolic syndrome: A multicentric prospective cohort study Clinical trial training project of Southern Medical University (LC2016PY047, 2016), Science and Technique Program of Guangzhou (201604020015, 2015), and South Wisdom Valley Innovative Research Team Program (CXTD-004, 2014), The National Natural Science Foundation of China (81873620).

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


